

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 11.08.2018

To,
Head Listing Compliance,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Security Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today i.e. **Saturday, 11th August, 2018** (commenced at 05:00 P.M and concluded at 06:00 P.M.) has inter alia approved and passed the following resolutions:

1. Unaudited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended June 30, 2018.
2. Taking note of the Limited Review Report as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
3. Taking note of Statement of Investor Complaints/Grievances under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended June 30, 2018.
4. The Board considered and approved draft of **Notice of Annual General Meeting** of the Company to be held on **Friday, 28th September, 2018 at 11:30 A.M** at Emerald Club, Supertech Emerald Court, Sector 93A Noida, Uttar Pradesh – 201304.
5. The Board considered and approved the **Board Report** for the year ended on **31st March, 2018**.
6. The Board considered and approved appointment of **Ms. Preeti Jain, Practicing Company Secretary, as the Scrutinizer** for conducting the e-voting process in a fair and transparent manner for the purpose of Annual General Meeting of the Company.

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

7. The Board fixed the Book Closure date from **22nd September, 2018 to 28th September, 2018**(both days inclusive).
8. The Board fixed the cut-off date as **Friday, 21st September, 2018** for providing e-voting services.
9. The Board fixed E-Voting period for the Annual General Meeting to be from **25th September, 2018 (09:00 A.M.) to 27th September, 2018 (05:00 P.M)**

Kindly take the above information on your records.

Thanking you,

Yours faithfully,
For **Raymed Labs Limited**

Ajai Goyal
Whole Time Director
DIN: 02636418

RAYMED LABS LIMITED

REGD. OFFICE : 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304

Phone: 0120-2426900, 9412700300;

E-mail: raymedlabs@rediffmail.com; Website: www.raymedlab.com,

CIN : L24111UP1992PLC014240

Statement of Unaudited Financial Results for the Quarter ended June 30, 2018 Amt. (In Lacs)

Particulars	Quarter Ended			Year Ended
	Quarter ended 30-06-2018	Preceding 3 month ended 31-03-2018	Corresponding 3 month ended in the previous year 30-06-2017	Year ended 31-03-2018
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from Operations	-	-	-	-
II. Other Income	0.30	0.30	0.30	1.20
III. Total Income (I +II)	0.30	0.30	0.30	1.20
IV. Expenses	-	-	-	-
Cost of Material Consumed	-	-	-	-
Purchases of Stock-in-trade	-	-	-	-
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	-	-	-	-
Employee Benefits Expenses	0.23	0.23	0.23	1.06
Finance Costs	-	-	-	-
Depreciation and amortisation expenses	0.16	0.17	0.17	0.68
Other Expenses	0.47	0.79	0.41	2.26
Total Expenses (IV)	0.86	1.19	0.81	4.00
V. Profit/(Loss) before exceptional items and tax (III- IV)	-0.56	-0.89	-0.51	-2.80
VI. Exceptional items	2.95	-	2.88	2.88
VII. Profit/(Loss) before tax (V-VI)	-3.51	-0.89	-3.39	-5.68
VIII. Tax Expense	-	-	-	-
(1) Current tax	-	-	-	-
(2) Deferred tax	-	-	-	-
(3) Previous Year Tax	-	-	-	-
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-3.51	-0.89	-3.39	-5.68
X. Profit/(Loss) from discontinued operations	-	-	-	-
XI. Tax expense of discontinued operations	-	-	-	-
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-
XIII. Profit/(Loss) for the period (IX+XII)	-3.51	-0.89	-3.39	-5.68
XIV. Other Comprehensive Income	-	-	-	-
(A) (i) Items that will not be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
(B) (i) Items that will be classified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	-3.51	-0.89	-3.39	-5.68
XVI. Earnings per equity share (for continuing operation):				
(1) Basic	-0.082	-0.021	-0.079	-0.133
(2) Diluted	-0.082	-0.021	-0.079	-0.133

XVII. Earnings per equity share (for discontinued operation):				
(1) Basic	-	-	-	-
(2) Diluted	-	-	-	-
XVIII. Earnings per equity share (for discontinued & continuing operations)				
(1) Basic	-0.082	-0.021	-0.079	-0.133
(2) Diluted	-0.082	-0.021	-0.079	-0.133

Notes:

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 11th, August 2018.

(2) The above results have been reviewed by the Statutory Auditors of the Company.

(3) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

(4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification

(5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

For Raymed Labs Limited

Ajai Goyal

Whole Time Director

DIN: 02636418

Add: 103 Emperor 1, Supertech Emerald Court, Sector 93A

Noida, UP – 201304

Date: 11.08.2018

Place: Noida



A. Kay Mehra & Co.

CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009

Tel. No. : 011-42461274, 9891295255, 9818708294

E-mail : akmca1969@gmail.com Website : www.akmca.in

Limited Review Report on unaudited quarterly financial results of Raymed Labs Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors

Raymed Labs Limited

703, Aster 7, Supertech Emerald Court,
Sector 93A, Noida- 201304

We have reviewed the accompanying statement of unaudited financial results ("The Statement") of Raymed Labs Limited ("The Company") for the quarter ended **June 30, 2018**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2018 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: August 11, 2018

For A. Kay Mehra & Co.
Chartered Accountants
(F.R.N. 050004C)



CA Deepak Suneja
Partner
(Membership No. 501957)